Looking to bolster its planned Phase III trial with TP-434 (eravacycline) for complicated intra-abdominal infections, Tetraphase Pharmaceuticals Inc. filed for an initial public offering (IPO) that would raise up to $86.2 million, though neither the targeted number of shares nor the price of each was disclosed.